Pharsight

1. Drug name - ATROVENT HFA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8474447	BOEHRINGER INGELHEIM	Inhaler device	Jan, 2030 (7 years from now)

Drugs and Companies using IPRATROPIUM BROMIDE ingredient

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

Strength	Dosage	Availability
0.021MG/INH	AEROSOL, METERED;INHALATION	Prescription

2. Drug name - COMBIVENT RESPIMAT

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7284474	BOEHRINGER INGELHEIM	Piston-pumping system having o-ring seal properties	Aug, 2024 (1 year, 10 months from now)
US7896264	BOEHRINGER INGELHEIM	Microstructured high pressure nozzle with built-in filter function	May, 2025 (2 years from now)
US7396341	BOEHRINGER INGELHEIM	Blocking device for a locking stressing mechanism having a spring-actuated output drive device	Oct, 2026 (4 years from now)
US9027967	BOEHRINGER INGELHEIM	Device for clamping a fluidic component	Mar, 2027 (4 years from now)
US7837235	BOEHRINGER INGELHEIM	Device for clamping a fluidic component	Mar, 2028 (5 years from now)
US8733341	BOEHRINGER INGELHEIM	Atomizer and method of atomizing fluid with a nozzle rinsing mechanism	Oct, 2030 (8 years from now)

Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient

Treatment: NA

Dosage: SPRAY, METERED;INHALATION

Strength	Dosage	Availability
EQ 0.1MG BASE/INH;0.02MG/INH	SPRAY, METERED;INHALATION	Prescription

3. Drug name - GILOTRIF

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE43431	BOEHRINGER INGELHEIM	Quinazoline derivatives and pharmaceutical compositions containing them	Jan, 2026 (3 years from now)
US8426586	BOEHRINGER INGELHEIM	Process for preparing amino crotonyl compounds	Oct, 2029 (7 years from now)
CN101402631A	BOEHRINGER INGELHEIM	Amino Quinazoline Dimaleate, Method For Production Thereof And Use Thereof	Dec, 2013 (8 years ago)
CN1481370A	BOEHRINGER INGELHEIM	Quinazoline Derivatives, Pharmaceutical Compositions Containing These Compounds, Their Use And Process For Their Manufacture	Dec, 2021 (9 months ago)
CN1277822C	BOEHRINGER INGELHEIM	Quinazoline Derivatives, Pharmaceutical Compositions Containing These Compounds, Their Use And Process For Their Manufacture	Dec, 2021 (9 months ago)
CN1867564A	BOEHRINGER INGELHEIM	Method For Preparing Amino Croton Radical Compound	Oct, 2024 (2 years from now)
CN1867564B	BOEHRINGER INGELHEIM	Method For Preparing Amino Croton Based Compound	Oct, 2024 (2 years from now)
IN224186B	BOEHRINGER INGELHEIM	Quinazoline Compounds And Process Thereof	Dec, 2021 (9 months ago)
IN200300822P1	BOEHRINGER INGELHEIM	Quinazoline Compounds And Process Thereof	Dec, 2021 (9 months ago)
EP2508521B1	BOEHRINGER INGELHEIM	Method For The Production Of Amino Crotonyl Compounds	Oct, 2024 (2 years from now)
EP2508521A2	BOEHRINGER INGELHEIM	Dimaleat Of An Amino Crotonyl Compound And Method Of Production Thereof	Oct, 2024 (2 years from now)
EP1678165B1	BOEHRINGER INGELHEIM	Method For The Production Of Amino Crotonyl Compounds	Oct, 2024 (2 years from now)
EP2508521A3	BOEHRINGER INGELHEIM	Method For The Production Of Amino Crotonyl Compounds	Oct, 2024 (2 years from now)
EP1678165A2	BOEHRINGER INGELHEIM	Method For The Production Of Amino Crotonyl Compounds	Oct, 2024 (2 years from now)
EP1345910B1	BOEHRINGER INGELHEIM	Quinazoline Derivatives, Medicaments Containing Said Compounds, Their Utilization And Method For The Production Thereof	Dec, 2026 (4 years from now)
EP1345910A1	BOEHRINGER INGELHEIM	Quinazoline Derivatives, Medicaments Containing Said Compounds, Their Utilization And Method For The Production Thereof	Dec, 2026 (4 years from now)
EP1345910B9	BOEHRINGER INGELHEIM	Quinazoline Derivatives, Medicaments Containing Said Compounds, Their Utilization And Method For The Production Thereof	Dec, 2026 (4 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE43431 (Pediatric)	BOEHRINGER INGELHEIM	Quinazoline derivatives and pharmaceutical compositions containing them	Jul, 2026 (3 years from now)
US9539258	BOEHRINGER INGELHEIM	Quinazoline derivatives for the treatment of cancer diseases	Nov, 2026 (4 years from now)
US9539258 (Pediatric)	BOEHRINGER INGELHEIM	Quinazoline derivatives for the treatment of cancer diseases	May, 2027 (4 years from now)
US8545884	BOEHRINGER INGELHEIM	Solid pharmaceutical formulations comprising BIBW 2992	Dec, 2029 (7 years from now)
US8426586 (Pediatric)	BOEHRINGER INGELHEIM	Process for preparing amino crotonyl compounds	Apr, 2030 (7 years from now)
US8545884 (Pediatric)	BOEHRINGER INGELHEIM	Solid pharmaceutical formulations comprising BIBW 2992	Jun, 2030 (7 years from now)
US10004743	BOEHRINGER INGELHEIM	Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient	Jul, 2030 (7 years from now)
US10004743 (Pediatric)	BOEHRINGER INGELHEIM	Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient	Jan, 2031 (8 years from now)

Drugs and Companies using AFATINIB DIMALEATE ingredient

Treatment: Treatment of patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 20MG BASE	TABLET;ORAL	Prescription
EQ 30MG BASE	TABLET;ORAL	Prescription
EQ 40MG BASE	TABLET;ORAL	Prescription

4. Drug name - GLYXAMBI

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7407955	BOEHRINGER INGELHEIM	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	May, 2025 (2 years from now)
US7713938	BOEHRINGER INGELHEIM	Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments	Apr, 2027 (4 years from now)
US7579449	BOEHRINGER INGELHEIM	Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture	Aug, 2028 (5 years from now)
CN1930141A	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	May, 2014 (8 years ago)
CN103450129A	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	May, 2021 (1 year, 4 months ago)
CN103450129B	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	May, 2021 (1 year, 4 months ago)
CN103467423A	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	Sep, 2021 (1 year, 22 days ago)
CN103435581A	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	Sep, 2021 (1 year, 22 days ago)
CN103435581B	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Phenyl Derivatives, Medicaments Containing Said Compounds, Use Thereof, And Method For Manufacturing The Same	Sep, 2021 (1 year, 22 days ago)
CN103467423B	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	Sep, 2021 (1 year, 22 days ago)
CN101503408B	BOEHRINGER INGELHEIM	8 - (3 - - Piperidine-1 - - Yl] - Xanthine Compounds	Aug, 2023 (10 months from now)
CN1675212A	BOEHRINGER INGELHEIM	8 - (3-Amino-Piperidin-1-Yl] - Xanthine, Its Preparation Method And Its Purpose As A Pharmaceutical Preparation	Aug, 2023 (10 months from now)
CN105001222B	BOEHRINGER INGELHEIM	8 - (3-Amino-Piperidin-1-Yl] - Xanthine, Its Preparation Method And Purpose As Medicine Preparation	Aug, 2023 (10 months from now)
CN100522962C	BOEHRINGER INGELHEIM	8 - [3-Amino-Piperidin-1-Yl] - Xanthine, Its Preparation Method And Purpose As Medicine Preparation	Aug, 2023 (10 months from now)
CN101503408A	BOEHRINGER INGELHEIM	8-(3-Amino-Piperidin-1-Yl)-Xanthines Compound	Aug, 2023 (10 months from now)
CN101503409A	BOEHRINGER INGELHEIM	8-(3-Amino-Piperidin-1-Yl)-Xanthines, The Production Thereof And The Use Of The Same As Medicaments	Aug, 2023 (10 months from now)
CN102964347B	BOEHRINGER INGELHEIM	8-[3-Amino-Piperidin-1-Yl]-Xanthines, Preparation Method Thereof And Application Thereof As Medicament	Aug, 2023 (10 months from now)
CN102964347A	BOEHRINGER INGELHEIM	8 - (3 - - Piperidine-1 - - Yl] - Xanthine Compound, Preparation Method And Use Thereof As Pharmaceutical Preparation	Aug, 2023 (10 months from now)
CN101503409B	BOEHRINGER INGELHEIM	8 - [3-Amino-Piperidin-L-Yl] - Xanthines, Processes For Their Preparation And Their Use As Pharmaceutical Preparations	Aug, 2023 (10 months from now)
CN105001222A	BOEHRINGER INGELHEIM	8-[3-Amino-Piperidin-1-Yl]-Xanthines, Preparation Method Thereof And Application Thereof As Medicament	Aug, 2023 (10 months from now)
CN101155794B	BOEHRINGER INGELHEIM	1 - -4-[Beta] -D - Glucopyranose - -1) -2-[4 - ((S) - Tetrahydrofuran - -3 - Yloxy) - Benzyl] - Crystal Form Of Benzene, Preparation Method Thereof And Use For Preparing Medicine	May, 2026 (3 years from now)
CN101155794A	BOEHRINGER INGELHEIM	Crystalline Form Of 1-Chloro-4-(Betal-D-Glucopyranos-1-Radical)-2-[4-((S)-Tetrahydrofuran-3-Yloxy)-Benzyl]-Benzene, A Method For Its Preparation And The Use Thereof For Preparing Medicaments	May, 2026 (3 years from now)
IN200500567P1	BOEHRINGER INGELHEIM	8-(3-Aminopiperidin-1-Yl)-Xanthine Compounds	Aug, 2023 (10 months from now)
IN243301B	BOEHRINGER INGELHEIM	8-(3-Aminopiperidin-1-Yl)-Xanthine Compounds	Aug, 2023 (10 months from now)
IN200604844P1	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	Mar, 2025 (2 years from now)
IN268846B	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzenol Derivative, Drug Containing Said Compound, The Use Thereof And Method For The Production Thereof	Mar, 2025 (2 years from now)
EP1828216B1	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzene Derivatives, Medicaments Containing Such Compounds, Their Use And Process For Their Manufacture	Dec, 2025 (3 years from now)
EP1828216A2	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzene Derivatives, Medicaments Containing Such Compounds, Their Use And Process For Their Manufacture	Dec, 2025 (3 years from now)
EP1888552A1	BOEHRINGER INGELHEIM	Crystalline Form Of 1-Chloro-4-(ß-D-Glucopyranos-1-Yl)-2-[4-((S)-Tetrahydrofuran-3-Yloxy)-Benzyl]-Benzene, A Method For Its Preparation And The Use Thereof For Preparing Medicaments	May, 2026 (3 years from now)
EP1888552B1	BOEHRINGER INGELHEIM	Crystalline Form Of 1-Chloro-4-(ß-D-Glucopyranos-1-Yl)-2-[4-((S)-Tetrahydrofuran-3-Yloxy)-Benzyl]-Benzene, A Method For Its Preparation And The Use Thereof For Preparing Medicaments	May, 2026 (3 years from now)
EP1532149B9	BOEHRINGER INGELHEIM	8-[3-Amino-Piperidin-1-Yl]-Xanthines, The Production Thereof And The Use Of The Same As Medicaments	Aug, 2026 (3 years from now)
EP1532149A2	BOEHRINGER INGELHEIM	8-[3-Amino-Piperidin-1-Yl]-Xanthines, The Production Thereof And The Use Of The Same As Medicaments	Aug, 2026 (3 years from now)
EP1532149B1	BOEHRINGER INGELHEIM	8-[3-Amino-Piperidin-1-Yl]-Xanthines, The Production Thereof And The Use Of The Same As Medicaments	Aug, 2026 (3 years from now)
EP1730131B1	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	May, 2029 (6 years from now)
EP1730131A1	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	May, 2029 (6 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8178541	BOEHRINGER INGELHEIM	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	Aug, 2023 (10 months from now)
US8119648	BOEHRINGER INGELHEIM	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	Aug, 2023 (10 months from now)
US8883805	BOEHRINGER INGELHEIM	Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines	Nov, 2025 (3 years from now)
US11033552	BOEHRINGER INGELHEIM	DPP IV inhibitor formulations	May, 2027 (4 years from now)
US8673927	BOEHRINGER INGELHEIM	Uses of DPP-IV inhibitors	May, 2027 (4 years from now)
US9173859	BOEHRINGER INGELHEIM	Uses of DPP IV inhibitors	May, 2027 (4 years from now)
US8551957	BOEHRINGER INGELHEIM	Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate	Oct, 2029 (7 years from now)
US10258637	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Apr, 2034 (11 years from now)
US11090323	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Apr, 2034 (11 years from now)
US9949998	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Jun, 2034 (11 years from now)

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin (with or without insulin or a sulfonylurea); method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin (with or without metformin); Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin; Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin and metformin; Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of treating type 2 diabetes mellitus in a patient with renal impairment (30 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin

Dosage: TABLET;ORAL

Strength	Dosage	Availability
10MG;5MG	TABLET;ORAL	Prescription
25MG;5MG	TABLET;ORAL	Prescription

5. Drug name - JARDIANCE

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7713938	BOEHRINGER INGELHEIM	Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments	Apr, 2027 (4 years from now)
US7579449	BOEHRINGER INGELHEIM	Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture	Aug, 2028 (5 years from now)
CN1930141A	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	May, 2014 (8 years ago)
CN103450129B	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	May, 2021 (1 year, 4 months ago)
CN103450129A	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	May, 2021 (1 year, 4 months ago)
CN103467423A	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	Sep, 2021 (1 year, 22 days ago)
CN103435581A	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	Sep, 2021 (1 year, 22 days ago)
CN103435581B	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Phenyl Derivatives, Medicaments Containing Said Compounds, Use Thereof, And Method For Manufacturing The Same	Sep, 2021 (1 year, 22 days ago)
CN103467423B	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	Sep, 2021 (1 year, 22 days ago)
CN101155794B	BOEHRINGER INGELHEIM	1 - -4-[Beta] -D - Glucopyranose - -1) -2-[4 - ((S) - Tetrahydrofuran - -3 - Yloxy) - Benzyl] - Crystal Form Of Benzene, Preparation Method Thereof And Use For Preparing Medicine	May, 2026 (3 years from now)
CN101155794A	BOEHRINGER INGELHEIM	Crystalline Form Of 1-Chloro-4-(Betal-D-Glucopyranos-1-Radical)-2-[4-((S)-Tetrahydrofuran-3-Yloxy)-Benzyl]-Benzene, A Method For Its Preparation And The Use Thereof For Preparing Medicaments	May, 2026 (3 years from now)
IN200604844P1	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	Mar, 2025 (2 years from now)
IN268846B	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzenol Derivative, Drug Containing Said Compound, The Use Thereof And Method For The Production Thereof	Mar, 2025 (2 years from now)
EP1828216B1	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzene Derivatives, Medicaments Containing Such Compounds, Their Use And Process For Their Manufacture	Dec, 2025 (3 years from now)
EP1828216A2	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzene Derivatives, Medicaments Containing Such Compounds, Their Use And Process For Their Manufacture	Dec, 2025 (3 years from now)
EP1888552A1	BOEHRINGER INGELHEIM	Crystalline Form Of 1-Chloro-4-(ß-D-Glucopyranos-1-Yl)-2-[4-((S)-Tetrahydrofuran-3-Yloxy)-Benzyl]-Benzene, A Method For Its Preparation And The Use Thereof For Preparing Medicaments	May, 2026 (3 years from now)
EP1888552B1	BOEHRINGER INGELHEIM	Crystalline Form Of 1-Chloro-4-(ß-D-Glucopyranos-1-Yl)-2-[4-((S)-Tetrahydrofuran-3-Yloxy)-Benzyl]-Benzene, A Method For Its Preparation And The Use Thereof For Preparing Medicaments	May, 2026 (3 years from now)
EP1730131A1	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	May, 2029 (6 years from now)
EP1730131B1	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	May, 2029 (6 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8551957	BOEHRINGER INGELHEIM	Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate	Oct, 2029 (7 years from now)
US10258637	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Apr, 2034 (11 years from now)
US11090323	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Apr, 2034 (11 years from now)
US9949997	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	May, 2034 (11 years from now)
US9949998	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Jun, 2034 (11 years from now)

Drugs and Companies using EMPAGLIFLOZIN ingredient

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin; Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of treating type 2 diabetes mellitus in a patient with renal impairment (30 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of reducing the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and cardiovascular disease by once daily administration of 10 mg or 25 mg of empagliflozin; method for reducing the risk of cardiovascular death plus hospitalization for heart failure in adults with type 2 diabetes mellitus, heart failure and reduced ejection fraction by once daily administration of empagliflozin

Dosage: TABLET;ORAL

Strength	Dosage	Availability
10MG	TABLET;ORAL	Prescription
25MG	TABLET;ORAL	Prescription

6. Drug name - JENTADUETO

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7407955	BOEHRINGER INGELHEIM	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	May, 2025 (2 years from now)
CN101503408B	BOEHRINGER INGELHEIM	8 - (3 - - Piperidine-1 - - Yl] - Xanthine Compounds	Aug, 2023 (10 months from now)
CN1675212A	BOEHRINGER INGELHEIM	8 - (3-Amino-Piperidin-1-Yl] - Xanthine, Its Preparation Method And Its Purpose As A Pharmaceutical Preparation	Aug, 2023 (10 months from now)
CN102964347B	BOEHRINGER INGELHEIM	8-[3-Amino-Piperidin-1-Yl]-Xanthines, Preparation Method Thereof And Application Thereof As Medicament	Aug, 2023 (10 months from now)
CN102964347A	BOEHRINGER INGELHEIM	8 - (3 - - Piperidine-1 - - Yl] - Xanthine Compound, Preparation Method And Use Thereof As Pharmaceutical Preparation	Aug, 2023 (10 months from now)
CN101503409A	BOEHRINGER INGELHEIM	8-(3-Amino-Piperidin-1-Yl)-Xanthines, The Production Thereof And The Use Of The Same As Medicaments	Aug, 2023 (10 months from now)
CN105001222B	BOEHRINGER INGELHEIM	8 - (3-Amino-Piperidin-1-Yl] - Xanthine, Its Preparation Method And Purpose As Medicine Preparation	Aug, 2023 (10 months from now)
CN100522962C	BOEHRINGER INGELHEIM	8 - [3-Amino-Piperidin-1-Yl] - Xanthine, Its Preparation Method And Purpose As Medicine Preparation	Aug, 2023 (10 months from now)
CN101503409B	BOEHRINGER INGELHEIM	8 - [3-Amino-Piperidin-L-Yl] - Xanthines, Processes For Their Preparation And Their Use As Pharmaceutical Preparations	Aug, 2023 (10 months from now)
CN105001222A	BOEHRINGER INGELHEIM	8-[3-Amino-Piperidin-1-Yl]-Xanthines, Preparation Method Thereof And Application Thereof As Medicament	Aug, 2023 (10 months from now)
CN101503408A	BOEHRINGER INGELHEIM	8-(3-Amino-Piperidin-1-Yl)-Xanthines Compound	Aug, 2023 (10 months from now)
IN200500567P1	BOEHRINGER INGELHEIM	8-(3-Aminopiperidin-1-Yl)-Xanthine Compounds	Aug, 2023 (10 months from now)
IN243301B	BOEHRINGER INGELHEIM	8-(3-Aminopiperidin-1-Yl)-Xanthine Compounds	Aug, 2023 (10 months from now)
EP1532149B9	BOEHRINGER INGELHEIM	8-[3-Amino-Piperidin-1-Yl]-Xanthines, The Production Thereof And The Use Of The Same As Medicaments	Aug, 2026 (3 years from now)
EP1532149A2	BOEHRINGER INGELHEIM	8-[3-Amino-Piperidin-1-Yl]-Xanthines, The Production Thereof And The Use Of The Same As Medicaments	Aug, 2026 (3 years from now)
EP1532149B1	BOEHRINGER INGELHEIM	8-[3-Amino-Piperidin-1-Yl]-Xanthines, The Production Thereof And The Use Of The Same As Medicaments	Aug, 2026 (3 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8119648	BOEHRINGER INGELHEIM	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	Aug, 2023 (10 months from now)
US8178541	BOEHRINGER INGELHEIM	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	Aug, 2023 (10 months from now)
US8883805	BOEHRINGER INGELHEIM	Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines	Nov, 2025 (3 years from now)
US8673927	BOEHRINGER INGELHEIM	Uses of DPP-IV inhibitors	May, 2027 (4 years from now)
US9415016	BOEHRINGER INGELHEIM	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	Apr, 2029 (6 years from now)
US10973827	BOEHRINGER INGELHEIM	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	Apr, 2029 (6 years from now)
US10022379	BOEHRINGER INGELHEIM	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	Apr, 2029 (6 years from now)
US9155705	BOEHRINGER INGELHEIM	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	May, 2030 (7 years from now)
US8846695	BOEHRINGER INGELHEIM	Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor	Jun, 2030 (7 years from now)

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Dosage: TABLET;ORAL

Strength	Dosage	Availability
2.5MG;1GM	TABLET;ORAL	Prescription
2.5MG;500MG	TABLET;ORAL	Prescription
2.5MG;850MG	TABLET;ORAL	Prescription

7. Drug name - JENTADUETO XR

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7407955	BOEHRINGER INGELHEIM	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	May, 2025 (2 years from now)
CN101503408B	BOEHRINGER INGELHEIM	8 - (3 - - Piperidine-1 - - Yl] - Xanthine Compounds	Aug, 2023 (10 months from now)
CN1675212A	BOEHRINGER INGELHEIM	8 - (3-Amino-Piperidin-1-Yl] - Xanthine, Its Preparation Method And Its Purpose As A Pharmaceutical Preparation	Aug, 2023 (10 months from now)
CN102964347B	BOEHRINGER INGELHEIM	8-[3-Amino-Piperidin-1-Yl]-Xanthines, Preparation Method Thereof And Application Thereof As Medicament	Aug, 2023 (10 months from now)
CN102964347A	BOEHRINGER INGELHEIM	8 - (3 - - Piperidine-1 - - Yl] - Xanthine Compound, Preparation Method And Use Thereof As Pharmaceutical Preparation	Aug, 2023 (10 months from now)
CN101503409A	BOEHRINGER INGELHEIM	8-(3-Amino-Piperidin-1-Yl)-Xanthines, The Production Thereof And The Use Of The Same As Medicaments	Aug, 2023 (10 months from now)
CN105001222B	BOEHRINGER INGELHEIM	8 - (3-Amino-Piperidin-1-Yl] - Xanthine, Its Preparation Method And Purpose As Medicine Preparation	Aug, 2023 (10 months from now)
CN100522962C	BOEHRINGER INGELHEIM	8 - [3-Amino-Piperidin-1-Yl] - Xanthine, Its Preparation Method And Purpose As Medicine Preparation	Aug, 2023 (10 months from now)
CN101503409B	BOEHRINGER INGELHEIM	8 - [3-Amino-Piperidin-L-Yl] - Xanthines, Processes For Their Preparation And Their Use As Pharmaceutical Preparations	Aug, 2023 (10 months from now)
CN105001222A	BOEHRINGER INGELHEIM	8-[3-Amino-Piperidin-1-Yl]-Xanthines, Preparation Method Thereof And Application Thereof As Medicament	Aug, 2023 (10 months from now)
CN101503408A	BOEHRINGER INGELHEIM	8-(3-Amino-Piperidin-1-Yl)-Xanthines Compound	Aug, 2023 (10 months from now)
IN200500567P1	BOEHRINGER INGELHEIM	8-(3-Aminopiperidin-1-Yl)-Xanthine Compounds	Aug, 2023 (10 months from now)
IN243301B	BOEHRINGER INGELHEIM	8-(3-Aminopiperidin-1-Yl)-Xanthine Compounds	Aug, 2023 (10 months from now)
EP1532149B9	BOEHRINGER INGELHEIM	8-[3-Amino-Piperidin-1-Yl]-Xanthines, The Production Thereof And The Use Of The Same As Medicaments	Aug, 2026 (3 years from now)
EP1532149A2	BOEHRINGER INGELHEIM	8-[3-Amino-Piperidin-1-Yl]-Xanthines, The Production Thereof And The Use Of The Same As Medicaments	Aug, 2026 (3 years from now)
EP1532149B1	BOEHRINGER INGELHEIM	8-[3-Amino-Piperidin-1-Yl]-Xanthines, The Production Thereof And The Use Of The Same As Medicaments	Aug, 2026 (3 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8119648	BOEHRINGER INGELHEIM	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	Aug, 2023 (10 months from now)
US8178541	BOEHRINGER INGELHEIM	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	Aug, 2023 (10 months from now)
US8883805	BOEHRINGER INGELHEIM	Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines	Nov, 2025 (3 years from now)
US8673927	BOEHRINGER INGELHEIM	Uses of DPP-IV inhibitors	May, 2027 (4 years from now)
US9173859	BOEHRINGER INGELHEIM	Uses of DPP IV inhibitors	May, 2027 (4 years from now)
US9415016	BOEHRINGER INGELHEIM	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	Apr, 2029 (6 years from now)
US10022379	BOEHRINGER INGELHEIM	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	Apr, 2029 (6 years from now)
US9155705	BOEHRINGER INGELHEIM	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	May, 2030 (7 years from now)
US9555001	BOEHRINGER INGELHEIM	Pharmaceutical composition and uses thereof	Mar, 2033 (10 years from now)

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin and, optionally, a sulfonylurea; Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin; Use of a pharmaceutical composition comprising linagliptin, metformin and a basic amino acid to treat type 2 diabetes mellitus; Method of treating type 2 diabetes in patients with insufficient glycemic control despite therapy with one or more conventional antihyperglycemic agents by administering linagliptin in combination with metformin; method of treating type 2 diabetes in patients who have not been previously treated with an antihyperglycemic agent by administering linagliptin in combination with metformin

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
2.5MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription
5MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription

8. Drug name - MICARDIS

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8003679	BOEHRINGER INGELHEIM	Use of inhibitors of the renin-angiotensin system	Oct, 2022 (3 days from now)

Drugs and Companies using TELMISARTAN ingredient

Treatment: Treatment or prevention of stroke

Dosage: TABLET;ORAL

Strength	Dosage	Availability
20MG	TABLET;ORAL	Prescription
40MG	TABLET;ORAL	Prescription
80MG	TABLET;ORAL	Prescription

9. Drug name - MIRAPEX ER

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7695734	BOEHRINGER INGELHEIM	Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof	Apr, 2028 (5 years from now)
US8679533	BOEHRINGER INGELHEIM	Pramipexole once-daily dosage form	Sep, 2029 (6 years from now)

Drugs and Companies using PRAMIPEXOLE DIHYDROCHLORIDE ingredient

Treatment: Treatment of parkinson's disease

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
0.375MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
0.75MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
1.5MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
2.25MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
3MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
3.75MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
4.5MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

10. Drug name - OFEV

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7119093	BOEHRINGER INGELHEIM	3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition	Feb, 2024 (1 year, 4 months from now)
US6762180	BOEHRINGER INGELHEIM	Substituted indolines which inhibit receptor tyrosine kinases	Oct, 2025 (2 years from now)
CN1391557A	BOEHRINGER INGELHEIM	6-Position Substituted Dihydroindole Ketone, Its Preparation And Its Use As A Pharmaceutical Composition	Oct, 2020 (1 year, 11 months ago)
CN100455568C	BOEHRINGER INGELHEIM	6-Position Substituted Dihydroindole Ketone, Its Preparation And Its Use As A Pharmaceutical Composition	Oct, 2020 (1 year, 11 months ago)
CN100351235C	BOEHRINGER INGELHEIM	2-Ketone-Ethyl Sulfonate Of A Pharmaceutical Composition And Its Preparation	Jul, 2023 (9 months from now)
CN1671660A	BOEHRINGER INGELHEIM	3-Z - [4 - (1 - (N - ((4-Methyl-Piperazin - -1 - Yl) - Methyl Carbonyl) - N-Methyl-Amino) - Phenylamino)--1 - Phenyl-Methylene]--6 - Methoxycarbonyl - -2 - Indolinone-Ethane Sulfonic Acid Salts And Their Use As A Pharmaceutical Composition	Jul, 2023 (9 months from now)
IN200200362P3	BOEHRINGER INGELHEIM	Indolinones Substituted In 6-Position, Preparation, And Their Use As Pharmaceutical Composition	Oct, 2020 (1 year, 11 months ago)
IN210415B	BOEHRINGER INGELHEIM	Indolinones Of General Formula I	Oct, 2020 (1 year, 11 months ago)
EP1224170B9	BOEHRINGER INGELHEIM	6-Position Substituted Indoline, Production And Use Thereof As A Medicament	Oct, 2020 (1 year, 11 months ago)
EP1224170B1	BOEHRINGER INGELHEIM	6-Position Substituted Indoline, Production And Use Thereof As A Medicament	Oct, 2020 (1 year, 11 months ago)
EP1224170A1	BOEHRINGER INGELHEIM	6-Position Substituted Indoline, Production And Use Thereof As A Medicament	Oct, 2020 (1 year, 11 months ago)
EP1527047B1	BOEHRINGER INGELHEIM	3-Z- 1-(4-(N-((4-Methyl-Piperazin-1-Yl)-Methylcarbonyl)-N-Me Thyl-Amino)-Anilino)-1-Phenyl-Methylene -6-Methoxycarbonyl-2 -Indolinone-Monoethanesulphonate And The Use Thereof As A Pharmaceutical Composition	Jul, 2023 (9 months from now)
EP1527047A1	BOEHRINGER INGELHEIM	3-Z- 1-(4-(N-((4-Methyl-Piperazin-1-Yl)-Methylcarbonyl)-N-Me Thyl-Amino)-Anilino)-1-Phenyl-Methylene -6-Methoxycarbonyl-2 -Indolinone-Monoethanesulphonate And The Use Thereof As A Pharmaceutical Composition	Jul, 2023 (9 months from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10154990	BOEHRINGER INGELHEIM	Medicaments for the treatment or prevention of fibrotic diseases	Dec, 2025 (3 years from now)
US10105323	BOEHRINGER INGELHEIM	Pharmaceutical dosage form for immediate release of an indolinone derivative	Jun, 2029 (6 years from now)
US9907756	BOEHRINGER INGELHEIM	Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative	Jun, 2029 (6 years from now)

Drugs and Companies using NINTEDANIB ESYLATE ingredient

Treatment: Use of nintedanib for slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (ssc-ild)

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 100MG BASE	CAPSULE;ORAL	Prescription
EQ 150MG BASE	CAPSULE;ORAL	Prescription

11. Drug name - PRADAXA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7932273	BOEHRINGER INGELHEIM	3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament	Sep, 2025 (2 years from now)
CN102167695B	BOEHRINGER INGELHEIM	Benzimidazole-Carbonyl-Pyridine-Amino-Ehtyl-Propionate Hemihyrate And Use Thereof	Aug, 2024 (1 year, 10 months from now)
CN1845917A	BOEHRINGER INGELHEIM	3 - [(2 - {[4 - (Methoxy Carbonyl Amino-Imino-Methyl) - Phenylamino] - Methyl} - 1-Methyl-1-H-Benzimidazole-5-Carbonyl) - Pyridin-2-Yl-Amino] - Ethyl Propionate-Mesylate And Its Use As A Pharmaceutical	Aug, 2024 (1 year, 10 months from now)
CN1845917B	BOEHRINGER INGELHEIM	3 - [(2 - {[4 - (Hexyloxy Carbonyl Amino-Imino-Methyl) - Benzene-Amino] - Methyl} -1--1H - Benzimidazole - -5 - Carbonyl) - Pyridin - -2 - Yl-Amino] - Ethyl Propionate Mesylate And Its Use As A Pharmaceutical	Aug, 2024 (1 year, 10 months from now)
CN102167695A	BOEHRINGER INGELHEIM	Benzimidazole Carbonyl Pyridine Amino Ethyl Propionate Semihydrate And Application Thereof	Aug, 2024 (1 year, 10 months from now)
IN200600924P1	BOEHRINGER INGELHEIM	3-[(2-{[4-(Hexyloxycarbonylaminoiminomethyl) Phenylamino]Methyl}-1-Methyl-1H-Benzimidazol-5-Carbonyl)Pyridin-2-Ylamino]Propionic Acid Ethylester Methansulfonate And Its Use As A Medicament	Aug, 2024 (1 year, 10 months from now)
IN256941B	BOEHRINGER INGELHEIM	Process For Preparing 324Hexyloxycarbonyla Minoiminomethylpheny Laminomethyl-1-Methyl-1H-Benzimidazol5Carbon Ylpyridine2Ylaminopro Pionate Methanesulfonate	Aug, 2024 (1 year, 10 months from now)
EP2060569B1	BOEHRINGER INGELHEIM	Ethyl 3-[(2-{[4-Hexyloxycarbonylamino-Imino-Methyl)-Phenylamino]-Methyl}-1-Methyl-1H-Benzimidazol-5-Carbonyl)-Pyridin-2-Yl-Amino]-Propionate Methanesulfonate Hemihydrate And Its Use As A Medicament	Aug, 2024 (1 year, 10 months from now)
EP2060569A1	BOEHRINGER INGELHEIM	Ethyl 3-[(2-{[4-Hexyloxycarbonylamino-Imino-Methyl)-Phenylamino]-Methyl}-1-Methyl-1H-Benzimidazol-5-Carbonyl)-Pyridin-2-Yl-Amino]-Propionate Methanesulfonate Hemihydrate And Its Use As A Medicament	Aug, 2024 (1 year, 10 months from now)
EP1660482A1	BOEHRINGER INGELHEIM	3-[(2-{ 4-(Hexyloxycarbonylamino-Imino-Methyl)-Phenylamino] -Methyl}-1-Methyl-1H-Benzimidazol-5-Carbonyl)-Pyridin-2-Yl-Amino -Propionic Acid Ethyl Ester Methane Sulphonate And Use Thereof As A Medicament	Aug, 2024 (1 year, 10 months from now)
EP1660482B1	BOEHRINGER INGELHEIM	3-[(2-{ 4-(Hexyloxycarbonylamino-Imino-Methyl)-Phenylamino] -Methyl}-1-Methyl-1H-Benzimidazol-5-Carbonyl)-Pyridin-2-Yl-Amino -Propionic Acid Ethyl Ester Methane Sulphonate And Use Thereof As A Medicament	Aug, 2024 (1 year, 10 months from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9925174	BOEHRINGER INGELHEIM	Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof	Jun, 2023 (8 months from now)
US9925174 (Pediatric)	BOEHRINGER INGELHEIM	Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof	Dec, 2023 (1 year, 2 months from now)
US7932273 (Pediatric)	BOEHRINGER INGELHEIM	3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament	Mar, 2026 (3 years from now)
US7866474	BOEHRINGER INGELHEIM	Film container	Aug, 2027 (4 years from now)
US7866474 (Pediatric)	BOEHRINGER INGELHEIM	Film container	Mar, 2028 (5 years from now)
US9034822	BOEHRINGER INGELHEIM	Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds	Jan, 2031 (8 years from now)
US9034822 (Pediatric)	BOEHRINGER INGELHEIM	Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds	Jul, 2031 (8 years from now)

Drugs and Companies using DABIGATRAN ETEXILATE MESYLATE ingredient

Treatment: Method of reversing the anticoagulant effect of dabigatran using idarucizumab

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 75MG BASE	CAPSULE;ORAL	Prescription
EQ 110MG BASE	CAPSULE;ORAL	Prescription
EQ 150MG BASE	CAPSULE;ORAL	Prescription

12. Drug name - SPIRIVA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8022082	BOEHRINGER INGELHEIM	Method for the administration of an anticholinergic by inhalation	Jan, 2026 (3 years from now)
US8022082 (Pediatric)	BOEHRINGER INGELHEIM	Method for the administration of an anticholinergic by inhalation	Jul, 2026 (3 years from now)
US7694676	BOEHRINGER INGELHEIM	Dry powder inhaler	Mar, 2027 (4 years from now)
US7694676 (Pediatric)	BOEHRINGER INGELHEIM	Dry powder inhaler	Sep, 2027 (4 years from now)
US9010323	BOEHRINGER INGELHEIM	Inhaler and sieve for an inhaler	Apr, 2030 (7 years from now)

Drugs and Companies using TIOTROPIUM BROMIDE ingredient

Treatment: Administration of an inhalable powder comprising tiotropium via device

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
EQ 0.018MG BASE/INH	POWDER;INHALATION	Prescription

13. Drug name - SPIRIVA RESPIMAT

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7284474	BOEHRINGER INGELHEIM	Piston-pumping system having o-ring seal properties	Aug, 2024 (1 year, 10 months from now)
US7284474 (Pediatric)	BOEHRINGER INGELHEIM	Piston-pumping system having o-ring seal properties	Feb, 2025 (2 years from now)
US7896264	BOEHRINGER INGELHEIM	Microstructured high pressure nozzle with built-in filter function	May, 2025 (2 years from now)
US7896264 (Pediatric)	BOEHRINGER INGELHEIM	Microstructured high pressure nozzle with built-in filter function	Nov, 2025 (3 years from now)
US7396341	BOEHRINGER INGELHEIM	Blocking device for a locking stressing mechanism having a spring-actuated output drive device	Oct, 2026 (4 years from now)
US9027967	BOEHRINGER INGELHEIM	Device for clamping a fluidic component	Mar, 2027 (4 years from now)
US7396341 (Pediatric)	BOEHRINGER INGELHEIM	Blocking device for a locking stressing mechanism having a spring-actuated output drive device	Apr, 2027 (4 years from now)
US9027967 (Pediatric)	BOEHRINGER INGELHEIM	Device for clamping a fluidic component	Oct, 2027 (4 years from now)
US7837235	BOEHRINGER INGELHEIM	Device for clamping a fluidic component	Mar, 2028 (5 years from now)
US7837235 (Pediatric)	BOEHRINGER INGELHEIM	Device for clamping a fluidic component	Sep, 2028 (5 years from now)
US8733341	BOEHRINGER INGELHEIM	Atomizer and method of atomizing fluid with a nozzle rinsing mechanism	Oct, 2030 (8 years from now)
US8733341 (Pediatric)	BOEHRINGER INGELHEIM	Atomizer and method of atomizing fluid with a nozzle rinsing mechanism	Apr, 2031 (8 years from now)

Drugs and Companies using TIOTROPIUM BROMIDE ingredient

Treatment: NA

Dosage: SPRAY, METERED;INHALATION

Strength	Dosage	Availability
EQ 0.00125MG BASE/INH	SPRAY, METERED;INHALATION	Prescription
EQ 0.0025MG BASE/INH	SPRAY, METERED;INHALATION	Prescription

14. Drug name - STIOLTO RESPIMAT

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7491719	BOEHRINGER INGELHEIM	Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments	Nov, 2023 (1 year, 1 month from now)
US7056916	BOEHRINGER INGELHEIM	Medicaments for the treatment of chronic obstructive pulmonary disease	Dec, 2023 (1 year, 2 months from now)
US7220742	BOEHRINGER INGELHEIM	Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments	May, 2025 (2 years from now)
US7727984	BOEHRINGER INGELHEIM	Medicaments for the treatment of chronic obstructive pulmonary disease	Jan, 2027 (4 years from now)
CN1713914A	BOEHRINGER INGELHEIM	New Medicine For Treating Chronic Obstructive Pulmonary Disease	Aug, 2010 (12 years ago)
CN101133039A	BOEHRINGER INGELHEIM	Novel Enantiomer Pure Beta-Agonists And Preparation Method And Use Thereof In Medicine Form	Mar, 2013 (9 years ago)
CN102827097B	BOEHRINGER INGELHEIM	Enantiomerically Pure Beta-Agonist, Its Preparation Method And Its Use In The Pharmaceutical Form	May, 2025 (2 years from now)
CN102827097A	BOEHRINGER INGELHEIM	Novel Enantiomerically Pure Beta-Agonist, Its Preparation Method And Its Use In The Pharmaceutical Form	May, 2025 (2 years from now)
IN200501999P1	BOEHRINGER INGELHEIM	Novel Medicaments For The Treatment Of Chronic Obstructive Pulmonary Disease	Nov, 2023 (1 year, 1 month from now)
IN225518B	BOEHRINGER INGELHEIM	Novel Substitued [1,1-Dimethyl-Ethyl-Amino)-I-Hydroxy-Ethyl]-6-Hydroxy-4H-Benzo[1,4]Oxazin-3-Ones) Compounds	Nov, 2023 (1 year, 1 month from now)
EP1562603B3	BOEHRINGER INGELHEIM	Novel Medicaments For The Treatment Of Chronic Obstructive Pulmonary Diseases	Jul, 2020 (2 years ago)
EP1562603B1	BOEHRINGER INGELHEIM	Novel Medicaments For The Treatment Of Chronic Obstructive Pulmonary Diseases	Jul, 2020 (2 years ago)
EP1562603A2	BOEHRINGER INGELHEIM	Novel Medicaments For The Treatment Of Chronic Obstructive Pulmonary Diseases	Jul, 2020 (2 years ago)
EP1789405B1	BOEHRINGER INGELHEIM	Novel Enantiomerically Pure Beta-Agonists, Method For The Production And The Use Thereof In The Form Of A Drug	May, 2025 (2 years from now)
EP1789405A1	BOEHRINGER INGELHEIM	Novel Enantiomerically Pure Beta-Agonists, Method For The Production And The Use Thereof In The Form Of A Drug	May, 2025 (2 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7786111	BOEHRINGER INGELHEIM	Medicaments for the treatment of chronic obstructive pulmonary disease	Nov, 2023 (1 year, 1 month from now)
US8044046	BOEHRINGER INGELHEIM	Medicaments for the treatment of chronic obstructive pulmonary disease	Nov, 2023 (1 year, 1 month from now)
US7284474	BOEHRINGER INGELHEIM	Piston-pumping system having o-ring seal properties	Aug, 2024 (1 year, 10 months from now)
US7284474 (Pediatric)	BOEHRINGER INGELHEIM	Piston-pumping system having o-ring seal properties	Feb, 2025 (2 years from now)
US8034809	BOEHRINGER INGELHEIM	Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments	May, 2025 (2 years from now)
US7896264	BOEHRINGER INGELHEIM	Microstructured high pressure nozzle with built-in filter function	May, 2025 (2 years from now)
US7396341	BOEHRINGER INGELHEIM	Blocking device for a locking stressing mechanism having a spring-actuated output drive device	Oct, 2026 (4 years from now)
US9027967	BOEHRINGER INGELHEIM	Device for clamping a fluidic component	Mar, 2027 (4 years from now)
US7396341 (Pediatric)	BOEHRINGER INGELHEIM	Blocking device for a locking stressing mechanism having a spring-actuated output drive device	Apr, 2027 (4 years from now)
US7837235	BOEHRINGER INGELHEIM	Device for clamping a fluidic component	Mar, 2028 (5 years from now)
US7837235 (Pediatric)	BOEHRINGER INGELHEIM	Device for clamping a fluidic component	Sep, 2028 (5 years from now)
US8733341	BOEHRINGER INGELHEIM	Atomizer and method of atomizing fluid with a nozzle rinsing mechanism	Oct, 2030 (8 years from now)

Drugs and Companies using OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE ingredient

Treatment: Treatment of copd

Dosage: SPRAY, METERED;INHALATION

Strength	Dosage	Availability
EQ 0.0025MG BASE/INH;EQ 0.0025MG BASE/INH	SPRAY, METERED;INHALATION	Prescription

15. Drug name - STRIVERDI RESPIMAT

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7491719	BOEHRINGER INGELHEIM	Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments	Nov, 2023 (1 year, 1 month from now)
US7056916	BOEHRINGER INGELHEIM	Medicaments for the treatment of chronic obstructive pulmonary disease	Dec, 2023 (1 year, 2 months from now)
US7220742	BOEHRINGER INGELHEIM	Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments	May, 2025 (2 years from now)
US7727984	BOEHRINGER INGELHEIM	Medicaments for the treatment of chronic obstructive pulmonary disease	Jan, 2027 (4 years from now)
CN1713914A	BOEHRINGER INGELHEIM	New Medicine For Treating Chronic Obstructive Pulmonary Disease	Aug, 2010 (12 years ago)
CN101133039A	BOEHRINGER INGELHEIM	Novel Enantiomer Pure Beta-Agonists And Preparation Method And Use Thereof In Medicine Form	Mar, 2013 (9 years ago)
CN102827097B	BOEHRINGER INGELHEIM	Enantiomerically Pure Beta-Agonist, Its Preparation Method And Its Use In The Pharmaceutical Form	May, 2025 (2 years from now)
CN102827097A	BOEHRINGER INGELHEIM	Novel Enantiomerically Pure Beta-Agonist, Its Preparation Method And Its Use In The Pharmaceutical Form	May, 2025 (2 years from now)
IN200501999P1	BOEHRINGER INGELHEIM	Novel Medicaments For The Treatment Of Chronic Obstructive Pulmonary Disease	Nov, 2023 (1 year, 1 month from now)
IN225518B	BOEHRINGER INGELHEIM	Novel Substitued [1,1-Dimethyl-Ethyl-Amino)-I-Hydroxy-Ethyl]-6-Hydroxy-4H-Benzo[1,4]Oxazin-3-Ones) Compounds	Nov, 2023 (1 year, 1 month from now)
EP1562603B3	BOEHRINGER INGELHEIM	Novel Medicaments For The Treatment Of Chronic Obstructive Pulmonary Diseases	Jul, 2020 (2 years ago)
EP1562603B1	BOEHRINGER INGELHEIM	Novel Medicaments For The Treatment Of Chronic Obstructive Pulmonary Diseases	Jul, 2020 (2 years ago)
EP1562603A2	BOEHRINGER INGELHEIM	Novel Medicaments For The Treatment Of Chronic Obstructive Pulmonary Diseases	Jul, 2020 (2 years ago)
EP1789405B1	BOEHRINGER INGELHEIM	Novel Enantiomerically Pure Beta-Agonists, Method For The Production And The Use Thereof In The Form Of A Drug	May, 2025 (2 years from now)
EP1789405A1	BOEHRINGER INGELHEIM	Novel Enantiomerically Pure Beta-Agonists, Method For The Production And The Use Thereof In The Form Of A Drug	May, 2025 (2 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8044046	BOEHRINGER INGELHEIM	Medicaments for the treatment of chronic obstructive pulmonary disease	Nov, 2023 (1 year, 1 month from now)
US7786111	BOEHRINGER INGELHEIM	Medicaments for the treatment of chronic obstructive pulmonary disease	Nov, 2023 (1 year, 1 month from now)
US7284474	BOEHRINGER INGELHEIM	Piston-pumping system having o-ring seal properties	Aug, 2024 (1 year, 10 months from now)
US8034809	BOEHRINGER INGELHEIM	Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments	May, 2025 (2 years from now)
US7896264	BOEHRINGER INGELHEIM	Microstructured high pressure nozzle with built-in filter function	May, 2025 (2 years from now)
US7396341	BOEHRINGER INGELHEIM	Blocking device for a locking stressing mechanism having a spring-actuated output drive device	Oct, 2026 (4 years from now)
US9027967	BOEHRINGER INGELHEIM	Device for clamping a fluidic component	Mar, 2027 (4 years from now)
US7837235	BOEHRINGER INGELHEIM	Device for clamping a fluidic component	Mar, 2028 (5 years from now)
US8733341	BOEHRINGER INGELHEIM	Atomizer and method of atomizing fluid with a nozzle rinsing mechanism	Oct, 2030 (8 years from now)

Drugs and Companies using OLODATEROL HYDROCHLORIDE ingredient

Treatment: Treatment of chronic obstructive pulmonary disease (copd), chronic bronchitis or emphysema

Dosage: SPRAY, METERED;INHALATION

Strength	Dosage	Availability
EQ 0.0025MG BASE/INH	SPRAY, METERED;INHALATION	Prescription

16. Drug name - SYNJARDY

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7713938	BOEHRINGER INGELHEIM	Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments	Apr, 2027 (4 years from now)
US7579449	BOEHRINGER INGELHEIM	Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture	Aug, 2028 (5 years from now)
CN1930141A	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	May, 2014 (8 years ago)
CN103450129B	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	May, 2021 (1 year, 4 months ago)
CN103450129A	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	May, 2021 (1 year, 4 months ago)
CN103467423A	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	Sep, 2021 (1 year, 22 days ago)
CN103435581A	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	Sep, 2021 (1 year, 22 days ago)
CN103435581B	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Phenyl Derivatives, Medicaments Containing Said Compounds, Use Thereof, And Method For Manufacturing The Same	Sep, 2021 (1 year, 22 days ago)
CN103467423B	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	Sep, 2021 (1 year, 22 days ago)
CN101155794B	BOEHRINGER INGELHEIM	1 - -4-[Beta] -D - Glucopyranose - -1) -2-[4 - ((S) - Tetrahydrofuran - -3 - Yloxy) - Benzyl] - Crystal Form Of Benzene, Preparation Method Thereof And Use For Preparing Medicine	May, 2026 (3 years from now)
CN101155794A	BOEHRINGER INGELHEIM	Crystalline Form Of 1-Chloro-4-(Betal-D-Glucopyranos-1-Radical)-2-[4-((S)-Tetrahydrofuran-3-Yloxy)-Benzyl]-Benzene, A Method For Its Preparation And The Use Thereof For Preparing Medicaments	May, 2026 (3 years from now)
IN200604844P1	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	Mar, 2025 (2 years from now)
IN268846B	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzenol Derivative, Drug Containing Said Compound, The Use Thereof And Method For The Production Thereof	Mar, 2025 (2 years from now)
EP1828216B1	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzene Derivatives, Medicaments Containing Such Compounds, Their Use And Process For Their Manufacture	Dec, 2025 (3 years from now)
EP1828216A2	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzene Derivatives, Medicaments Containing Such Compounds, Their Use And Process For Their Manufacture	Dec, 2025 (3 years from now)
EP1888552A1	BOEHRINGER INGELHEIM	Crystalline Form Of 1-Chloro-4-(ß-D-Glucopyranos-1-Yl)-2-[4-((S)-Tetrahydrofuran-3-Yloxy)-Benzyl]-Benzene, A Method For Its Preparation And The Use Thereof For Preparing Medicaments	May, 2026 (3 years from now)
EP1888552B1	BOEHRINGER INGELHEIM	Crystalline Form Of 1-Chloro-4-(ß-D-Glucopyranos-1-Yl)-2-[4-((S)-Tetrahydrofuran-3-Yloxy)-Benzyl]-Benzene, A Method For Its Preparation And The Use Thereof For Preparing Medicaments	May, 2026 (3 years from now)
EP1730131A1	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	May, 2029 (6 years from now)
EP1730131B1	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	May, 2029 (6 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10610489	BOEHRINGER INGELHEIM	Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof	Sep, 2030 (7 years from now)
US10258637	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Apr, 2034 (11 years from now)
US11090323	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Apr, 2034 (11 years from now)

Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of treating type 2 diabetes mellitus in a patent with renal impairment (egfr<60 ml/min/1.73 m2) by initiation of empagliflozin and metformin hcl if egfr>=45 ml/min/1.73 m2 and discontinuation if egfr<30 ml/min/1.73 m2

Dosage: TABLET;ORAL

Strength	Dosage	Availability
5MG;1GM	TABLET;ORAL	Prescription
5MG;500MG	TABLET;ORAL	Prescription
12.5MG;1GM	TABLET;ORAL	Prescription
12.5MG;500MG	TABLET;ORAL	Prescription

17. Drug name - SYNJARDY XR

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7713938	BOEHRINGER INGELHEIM	Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments	Apr, 2027 (4 years from now)
US7579449	BOEHRINGER INGELHEIM	Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture	Aug, 2028 (5 years from now)
CN1930141A	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	May, 2014 (8 years ago)
CN103450129B	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	May, 2021 (1 year, 4 months ago)
CN103450129A	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	May, 2021 (1 year, 4 months ago)
CN103467423A	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	Sep, 2021 (1 year, 22 days ago)
CN103435581A	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	Sep, 2021 (1 year, 22 days ago)
CN103435581B	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Phenyl Derivatives, Medicaments Containing Said Compounds, Use Thereof, And Method For Manufacturing The Same	Sep, 2021 (1 year, 22 days ago)
CN103467423B	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	Sep, 2021 (1 year, 22 days ago)
CN101155794B	BOEHRINGER INGELHEIM	1 - -4-[Beta] -D - Glucopyranose - -1) -2-[4 - ((S) - Tetrahydrofuran - -3 - Yloxy) - Benzyl] - Crystal Form Of Benzene, Preparation Method Thereof And Use For Preparing Medicine	May, 2026 (3 years from now)
CN101155794A	BOEHRINGER INGELHEIM	Crystalline Form Of 1-Chloro-4-(Betal-D-Glucopyranos-1-Radical)-2-[4-((S)-Tetrahydrofuran-3-Yloxy)-Benzyl]-Benzene, A Method For Its Preparation And The Use Thereof For Preparing Medicaments	May, 2026 (3 years from now)
IN200604844P1	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	Mar, 2025 (2 years from now)
IN268846B	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzenol Derivative, Drug Containing Said Compound, The Use Thereof And Method For The Production Thereof	Mar, 2025 (2 years from now)
EP1828216B1	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzene Derivatives, Medicaments Containing Such Compounds, Their Use And Process For Their Manufacture	Dec, 2025 (3 years from now)
EP1828216A2	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzene Derivatives, Medicaments Containing Such Compounds, Their Use And Process For Their Manufacture	Dec, 2025 (3 years from now)
EP1888552A1	BOEHRINGER INGELHEIM	Crystalline Form Of 1-Chloro-4-(ß-D-Glucopyranos-1-Yl)-2-[4-((S)-Tetrahydrofuran-3-Yloxy)-Benzyl]-Benzene, A Method For Its Preparation And The Use Thereof For Preparing Medicaments	May, 2026 (3 years from now)
EP1888552B1	BOEHRINGER INGELHEIM	Crystalline Form Of 1-Chloro-4-(ß-D-Glucopyranos-1-Yl)-2-[4-((S)-Tetrahydrofuran-3-Yloxy)-Benzyl]-Benzene, A Method For Its Preparation And The Use Thereof For Preparing Medicaments	May, 2026 (3 years from now)
EP1730131A1	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	May, 2029 (6 years from now)
EP1730131B1	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	May, 2029 (6 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10596120	BOEHRINGER INGELHEIM	Pharmaceutical compositions	Mar, 2032 (9 years from now)
US11090323	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Apr, 2034 (11 years from now)
US10258637	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Apr, 2034 (11 years from now)
US9949998	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Jun, 2034 (11 years from now)

Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: Treatment of a type 2 diabetes mellitus patient with insufficient glycemic control despite metformin therapy using a composition comprising an extended release core comprising metformin and an outer coating comprising empagliflozin; treatment of a treatment-naïve patient with inadequately controlled type 2 diabetes using a composition comprising an extended release core comprising metformin and an outer coating comprising empagliflozin; Method of treating type 2 diabetes mellitus in a patent with renal impairment (egfr<60 ml/min/1.73 m2) by initiation of empagliflozin and metformin hcl if egfr>=45 ml/min/1.73 m2 and discontinuation if egfr<30 ml/min/1.73 m2; Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
5MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription
10MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription
12.5MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription
25MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription

18. Drug name - TRADJENTA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7407955	BOEHRINGER INGELHEIM	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	May, 2025 (2 years from now)
CN101503408B	BOEHRINGER INGELHEIM	8 - (3 - - Piperidine-1 - - Yl] - Xanthine Compounds	Aug, 2023 (10 months from now)
CN1675212A	BOEHRINGER INGELHEIM	8 - (3-Amino-Piperidin-1-Yl] - Xanthine, Its Preparation Method And Its Purpose As A Pharmaceutical Preparation	Aug, 2023 (10 months from now)
CN102964347B	BOEHRINGER INGELHEIM	8-[3-Amino-Piperidin-1-Yl]-Xanthines, Preparation Method Thereof And Application Thereof As Medicament	Aug, 2023 (10 months from now)
CN102964347A	BOEHRINGER INGELHEIM	8 - (3 - - Piperidine-1 - - Yl] - Xanthine Compound, Preparation Method And Use Thereof As Pharmaceutical Preparation	Aug, 2023 (10 months from now)
CN101503409A	BOEHRINGER INGELHEIM	8-(3-Amino-Piperidin-1-Yl)-Xanthines, The Production Thereof And The Use Of The Same As Medicaments	Aug, 2023 (10 months from now)
CN105001222B	BOEHRINGER INGELHEIM	8 - (3-Amino-Piperidin-1-Yl] - Xanthine, Its Preparation Method And Purpose As Medicine Preparation	Aug, 2023 (10 months from now)
CN100522962C	BOEHRINGER INGELHEIM	8 - [3-Amino-Piperidin-1-Yl] - Xanthine, Its Preparation Method And Purpose As Medicine Preparation	Aug, 2023 (10 months from now)
CN101503409B	BOEHRINGER INGELHEIM	8 - [3-Amino-Piperidin-L-Yl] - Xanthines, Processes For Their Preparation And Their Use As Pharmaceutical Preparations	Aug, 2023 (10 months from now)
CN105001222A	BOEHRINGER INGELHEIM	8-[3-Amino-Piperidin-1-Yl]-Xanthines, Preparation Method Thereof And Application Thereof As Medicament	Aug, 2023 (10 months from now)
CN101503408A	BOEHRINGER INGELHEIM	8-(3-Amino-Piperidin-1-Yl)-Xanthines Compound	Aug, 2023 (10 months from now)
IN200500567P1	BOEHRINGER INGELHEIM	8-(3-Aminopiperidin-1-Yl)-Xanthine Compounds	Aug, 2023 (10 months from now)
IN243301B	BOEHRINGER INGELHEIM	8-(3-Aminopiperidin-1-Yl)-Xanthine Compounds	Aug, 2023 (10 months from now)
EP1532149B9	BOEHRINGER INGELHEIM	8-[3-Amino-Piperidin-1-Yl]-Xanthines, The Production Thereof And The Use Of The Same As Medicaments	Aug, 2026 (3 years from now)
EP1532149A2	BOEHRINGER INGELHEIM	8-[3-Amino-Piperidin-1-Yl]-Xanthines, The Production Thereof And The Use Of The Same As Medicaments	Aug, 2026 (3 years from now)
EP1532149B1	BOEHRINGER INGELHEIM	8-[3-Amino-Piperidin-1-Yl]-Xanthines, The Production Thereof And The Use Of The Same As Medicaments	Aug, 2026 (3 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8178541	BOEHRINGER INGELHEIM	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	Aug, 2023 (10 months from now)
US8119648	BOEHRINGER INGELHEIM	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	Aug, 2023 (10 months from now)
US8883805	BOEHRINGER INGELHEIM	Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines	Nov, 2025 (3 years from now)
US8673927	BOEHRINGER INGELHEIM	Uses of DPP-IV inhibitors	May, 2027 (4 years from now)
US11033552	BOEHRINGER INGELHEIM	DPP IV inhibitor formulations	May, 2027 (4 years from now)
US9486526	BOEHRINGER INGELHEIM	Treatment for diabetes in patients inappropriate for metformin therapy	Aug, 2029 (6 years from now)
US10034877	BOEHRINGER INGELHEIM	Treatment for diabetes in patients inappropriate for metformin therapy	Aug, 2029 (6 years from now)
US8846695	BOEHRINGER INGELHEIM	Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor	Jun, 2030 (7 years from now)
US8853156	BOEHRINGER INGELHEIM	Treatment for diabetes in patients inappropriate for metformin therapy	Mar, 2031 (8 years from now)

Drugs and Companies using LINAGLIPTIN ingredient

Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with sulfonlyurea; method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin and/or a sulfonylurea; method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with pioglitazone; method of treating type 2 diabetes mellitus by administering linagliptin in combination with insulin (with or without metformin and/or pioglitazone); Method of treating type 2 diabetes mellitus by administering linagliptin in combination with insulin (with or without metformin and/or pioglitazone); method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor; Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin; Method of treating type 2 diabetes mellitus in patients with severe chronic renal impairment and who are ineligible for metformin therapy by administering linagliptin; Treatment of type 2 diabetes mellitus in a patient with renal impairment and for whom metformin therapy is inappropriate by administering linagliptin without dose adjustment; Method of treating type 2 diabetes mellitus in patients with severe chronic renal impairment and for whom metformin therapy is inappropriate by administering linagliptin

Dosage: TABLET;ORAL

Strength	Dosage	Availability
5MG	TABLET;ORAL	Prescription

19. Drug name - TRIJARDY XR

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7407955	BOEHRINGER INGELHEIM	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	May, 2025 (2 years from now)
US7713938	BOEHRINGER INGELHEIM	Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments	Apr, 2027 (4 years from now)
US7579449	BOEHRINGER INGELHEIM	Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture	Aug, 2028 (5 years from now)
CN1930141A	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	May, 2014 (8 years ago)
CN103450129A	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	May, 2021 (1 year, 4 months ago)
CN103450129B	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	May, 2021 (1 year, 4 months ago)
CN103467423A	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	Sep, 2021 (1 year, 22 days ago)
CN103435581A	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	Sep, 2021 (1 year, 22 days ago)
CN103435581B	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Phenyl Derivatives, Medicaments Containing Said Compounds, Use Thereof, And Method For Manufacturing The Same	Sep, 2021 (1 year, 22 days ago)
CN103467423B	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	Sep, 2021 (1 year, 22 days ago)
CN101503408B	BOEHRINGER INGELHEIM	8 - (3 - - Piperidine-1 - - Yl] - Xanthine Compounds	Aug, 2023 (10 months from now)
CN1675212A	BOEHRINGER INGELHEIM	8 - (3-Amino-Piperidin-1-Yl] - Xanthine, Its Preparation Method And Its Purpose As A Pharmaceutical Preparation	Aug, 2023 (10 months from now)
CN105001222B	BOEHRINGER INGELHEIM	8 - (3-Amino-Piperidin-1-Yl] - Xanthine, Its Preparation Method And Purpose As Medicine Preparation	Aug, 2023 (10 months from now)
CN100522962C	BOEHRINGER INGELHEIM	8 - [3-Amino-Piperidin-1-Yl] - Xanthine, Its Preparation Method And Purpose As Medicine Preparation	Aug, 2023 (10 months from now)
CN101503408A	BOEHRINGER INGELHEIM	8-(3-Amino-Piperidin-1-Yl)-Xanthines Compound	Aug, 2023 (10 months from now)
CN101503409A	BOEHRINGER INGELHEIM	8-(3-Amino-Piperidin-1-Yl)-Xanthines, The Production Thereof And The Use Of The Same As Medicaments	Aug, 2023 (10 months from now)
CN102964347B	BOEHRINGER INGELHEIM	8-[3-Amino-Piperidin-1-Yl]-Xanthines, Preparation Method Thereof And Application Thereof As Medicament	Aug, 2023 (10 months from now)
CN102964347A	BOEHRINGER INGELHEIM	8 - (3 - - Piperidine-1 - - Yl] - Xanthine Compound, Preparation Method And Use Thereof As Pharmaceutical Preparation	Aug, 2023 (10 months from now)
CN101503409B	BOEHRINGER INGELHEIM	8 - [3-Amino-Piperidin-L-Yl] - Xanthines, Processes For Their Preparation And Their Use As Pharmaceutical Preparations	Aug, 2023 (10 months from now)
CN105001222A	BOEHRINGER INGELHEIM	8-[3-Amino-Piperidin-1-Yl]-Xanthines, Preparation Method Thereof And Application Thereof As Medicament	Aug, 2023 (10 months from now)
CN101155794B	BOEHRINGER INGELHEIM	1 - -4-[Beta] -D - Glucopyranose - -1) -2-[4 - ((S) - Tetrahydrofuran - -3 - Yloxy) - Benzyl] - Crystal Form Of Benzene, Preparation Method Thereof And Use For Preparing Medicine	May, 2026 (3 years from now)
CN101155794A	BOEHRINGER INGELHEIM	Crystalline Form Of 1-Chloro-4-(Betal-D-Glucopyranos-1-Radical)-2-[4-((S)-Tetrahydrofuran-3-Yloxy)-Benzyl]-Benzene, A Method For Its Preparation And The Use Thereof For Preparing Medicaments	May, 2026 (3 years from now)
IN200500567P1	BOEHRINGER INGELHEIM	8-(3-Aminopiperidin-1-Yl)-Xanthine Compounds	Aug, 2023 (10 months from now)
IN243301B	BOEHRINGER INGELHEIM	8-(3-Aminopiperidin-1-Yl)-Xanthine Compounds	Aug, 2023 (10 months from now)
IN200604844P1	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	Mar, 2025 (2 years from now)
IN268846B	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzenol Derivative, Drug Containing Said Compound, The Use Thereof And Method For The Production Thereof	Mar, 2025 (2 years from now)
EP1828216B1	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzene Derivatives, Medicaments Containing Such Compounds, Their Use And Process For Their Manufacture	Dec, 2025 (3 years from now)
EP1828216A2	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzene Derivatives, Medicaments Containing Such Compounds, Their Use And Process For Their Manufacture	Dec, 2025 (3 years from now)
EP1888552A1	BOEHRINGER INGELHEIM	Crystalline Form Of 1-Chloro-4-(ß-D-Glucopyranos-1-Yl)-2-[4-((S)-Tetrahydrofuran-3-Yloxy)-Benzyl]-Benzene, A Method For Its Preparation And The Use Thereof For Preparing Medicaments	May, 2026 (3 years from now)
EP1888552B1	BOEHRINGER INGELHEIM	Crystalline Form Of 1-Chloro-4-(ß-D-Glucopyranos-1-Yl)-2-[4-((S)-Tetrahydrofuran-3-Yloxy)-Benzyl]-Benzene, A Method For Its Preparation And The Use Thereof For Preparing Medicaments	May, 2026 (3 years from now)
EP1532149B9	BOEHRINGER INGELHEIM	8-[3-Amino-Piperidin-1-Yl]-Xanthines, The Production Thereof And The Use Of The Same As Medicaments	Aug, 2026 (3 years from now)
EP1532149A2	BOEHRINGER INGELHEIM	8-[3-Amino-Piperidin-1-Yl]-Xanthines, The Production Thereof And The Use Of The Same As Medicaments	Aug, 2026 (3 years from now)
EP1532149B1	BOEHRINGER INGELHEIM	8-[3-Amino-Piperidin-1-Yl]-Xanthines, The Production Thereof And The Use Of The Same As Medicaments	Aug, 2026 (3 years from now)
EP1730131B1	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	May, 2029 (6 years from now)
EP1730131A1	BOEHRINGER INGELHEIM	Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof	May, 2029 (6 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8178541	BOEHRINGER INGELHEIM	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	Aug, 2023 (10 months from now)
US8119648	BOEHRINGER INGELHEIM	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	Aug, 2023 (10 months from now)
US8883805	BOEHRINGER INGELHEIM	Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines	Nov, 2025 (3 years from now)
US10022379	BOEHRINGER INGELHEIM	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	Apr, 2029 (6 years from now)
US9415016	BOEHRINGER INGELHEIM	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	Apr, 2029 (6 years from now)
US8551957	BOEHRINGER INGELHEIM	Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate	Oct, 2029 (7 years from now)
US9155705	BOEHRINGER INGELHEIM	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	May, 2030 (7 years from now)
US10406172	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Jun, 2030 (7 years from now)
US10596120	BOEHRINGER INGELHEIM	Pharmaceutical compositions	Mar, 2032 (9 years from now)
US11090323	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Apr, 2034 (11 years from now)
US10258637	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Apr, 2034 (11 years from now)
US9949998	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Jun, 2034 (11 years from now)

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin and metformin; Method of treating type 2 diabetes using a pharmaceutical composition comprising linagliptin, metformin, empagliflozin and a basic amino acid; Method of treating type 2 diabetes mellitus using a pharmaceutical composition comprising empagliflozin, linagliptin and metformin; Method of treating a type 2 diabetes mellitus patient with insufficient glycemic control despite therapy with metformin using a pharmaceutical composition comprising empagliflozin, linagliptin and metformin; Treatment of a treatment-naive patient with inadequately controlled type 2 diabetes using a composition comprising an extended release core comprisingmetformin and an outer coating comprising empagliflozin and linagliptin; treatment of a type 2 diabetes mellitus patient with insufficient glycemic control despite metformin therapy using a composition comprising an extended release core comprising metformin and an outer coating comprising empagliflozin and linagliptin; Method of treating type 2 diabetes mellitus in a patient with renal impairment (egfr<60 ml/min/1.73 m2) by initiation of empagliflozin, linagliptin and metformin hcl if egfr>=45 ml/min/1.73 m2 and discontinuation if egfr <30 ml/min/1.73 m2; Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin in combination with linagliptin and metformin

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
5MG;2.5MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription
10MG;5MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription
12.5MG;2.5MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription
25MG;5MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription

20. Drug name - VIRAMUNE XR

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8460704	BOEHRINGER INGELHEIM	Extended release formulation of nevirapine	Mar, 2029 (6 years from now)

Drugs and Companies using NEVIRAPINE ingredient

Treatment: Treatment of hiv-1 by once daily administration

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
100MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
400MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

Pharsight

Drug Patents owned by Boehringer Ingelheim

1. Drug name - ATROVENT HFA

2. Drug name - COMBIVENT RESPIMAT

3. Drug name - GILOTRIF

4. Drug name - GLYXAMBI

5. Drug name - JARDIANCE

6. Drug name - JENTADUETO

7. Drug name - JENTADUETO XR

8. Drug name - MICARDIS

9. Drug name - MIRAPEX ER

10. Drug name - OFEV

11. Drug name - PRADAXA

12. Drug name - SPIRIVA

13. Drug name - SPIRIVA RESPIMAT

14. Drug name - STIOLTO RESPIMAT

15. Drug name - STRIVERDI RESPIMAT

16. Drug name - SYNJARDY

17. Drug name - SYNJARDY XR

18. Drug name - TRADJENTA

19. Drug name - TRIJARDY XR

20. Drug name - VIRAMUNE XR

availability in other generic markets.

Click on the highlighted region to filter.

Pharsight

Drug Patents owned by Boehringer Ingelheim

1. Drug name - ATROVENT HFA

2. Drug name - COMBIVENT RESPIMAT

3. Drug name - GILOTRIF

4. Drug name - GLYXAMBI

5. Drug name - JARDIANCE

6. Drug name - JENTADUETO

7. Drug name - JENTADUETO XR

8. Drug name - MICARDIS

9. Drug name - MIRAPEX ER

10. Drug name - OFEV

11. Drug name - PRADAXA

12. Drug name - SPIRIVA

13. Drug name - SPIRIVA RESPIMAT

14. Drug name - STIOLTO RESPIMAT

15. Drug name - STRIVERDI RESPIMAT

16. Drug name - SYNJARDY

17. Drug name - SYNJARDY XR

18. Drug name - TRADJENTA

19. Drug name - TRIJARDY XR

20. Drug name - VIRAMUNE XR

availability in other generic markets. Click on the highlighted region to filter.

availability in other generic markets.

Click on the highlighted region to filter.